Cognition and memory impairment are hallmarks of the pathological cascade of various neurodegenerative disorders. Herein, we developed a novel computational strategy with two-dimensional virtual screening for not only affinity but also specificity. We integrated the two-dimensional virtual screening with ligand screening for 3D shape, electrostatic similarity and local binding site similarity to find existing drugs that may reduce the signs of cognitive deficits. For the first time, we found that pazopanib, a tyrosine kinase inhibitor marketed for cancer treatment, inhibits acetylcholinesterase (AchE) activities at sub-micromolar concentration. We evaluated and compared the effects of intragastrically-administered pazopanib with donepezil, a marketed AchE inhibitor, in cognitive and behavioral assays including the novel object recognition test, Y maze and Morris water maze test. Surprisingly, we found that pazopanib can restore memory loss and cognitive dysfunction to a similar extent as donepezil in a dosage of 15 mg kg
Introduction
With the increase in the elderly population worldwide, neurodegenerative disorders such as Alzheimer's disease (AD), 1 Parkinson's disease (PD) 2 and Huntington's disease (HD) 3 remain to be devastating diseases for which effective treatments are urgently needed. Memory dysfunction and cognition impairment are the most common symptoms affecting patients with neurodegenerative diseases. 4 To date, only four approved small-molecule therapeutics are on the market, of which three are acetylcholinesterase (AchE) inhibitors (donepezil, rivastigmine and galanthamine), for the treatment of mild to moderate AD symptoms. 5 Unfortunately, there is no denitive evidence yet showing that the use of donepezil or other agents can alter the course of AD progression. Hence, the search is still on for molecules with tolerable side effects to benet older patients with neurodegenerative disorders.
Traditionally, binding affinity has been used as the criterion in the virtual screening process for drug discovery. Yet, binding specicity is also crucial in the practice of drug design and discovery. 6 We developed a novel way to quantify specicity 7,8 based on our energy landscape theory of ligand binding. 9, 10 The native binding mode and the non-native conformations during the binding between a ligand and a receptor are statistically distributed in energy. Herein, specicity is quantied by the ISR (Intrinsic Specicity Ratio) value, calculated as dE DE ffiffiffiffiffi 2S p , where dE is the energy gap between the native binding mode and the average non-native binding states, DE is the energy variance or spread of the non-native states and S is the congurational entropy measuring the size of the congurational space, which scales with the size of the system (number of atoms). In other words, the entropy S represents the congurational entropy measuring the size of the congurational space that scales with the size of the system (number of atoms), which is the ligand-receptor binding complex in our study.
In the current study, the receptor targets are xed as rigid, the ligands are exible with certain exible torsional bonds, the entropy S depends approximately linearly on the number of torsional bonds of each ligand molecule with a constant coefcient on the order of 1. S is only related to the size of the system, which is constant during the binding process for a specic ligand binding to the receptor. Consequently, a large ISR value leads to a high level of discrimination of the native binding mode from the non-native binding modes, which implies high intrinsic specicity. 9, 10 One can imagine a large receptor as composed of small receptors connected together through linkers. Then the explorations of the structures (binding modes) for the same (large) target and explorations of the sequences for different (small) receptors for the same ligand are approximately equivalent. 7, 8 Therefore, the intrinsic specicity is expected to be correlated with the conventional specicity of discriminating by affinities among different receptors for the same ligand 7, 8 for large receptors. In this way, one can quantify the intrinsic specicity with only the specic target and infer the conventional specicity without the need for searching through the entire receptor universe. The two-dimensional virtual screening strategy covering not only affinity but also specicity can be used to search for drug candidates such as inhibitors of COX-2, 7,8 human serum albumin (HSA) 11 and Ras protein 12 etc. In this work, we rst employed the two dimensional virtual screening strategy for 1385 FDA-approved small molecule drugs with AchE as the receptor structure. Interestingly, three tyrosine kinase inhibitors (TKIs), sorafenib, pazopanib and sunitinib stand out as three top hits. Meanwhile, we used ligand-based virtual screening with donepezil as the query molecule to search against the 1385 FDA-approved small molecule drugs retrieved from the DrugBank database. 13 The ligand virtual screening was performed by the ROCS program for similar three-dimensional shapes 14 and the EON program for electrostatics. 15 Consistent with the results from the above two-dimensional virtual screenings, three TKIs (sorafenib, pazopanib and sunitinib) are also among the top 50 hits of the ligand virtual screening. In addition, we employed a local binding site similarity screening 16, 17 with AchE as the query structure to search against a set of 1105 crystallographic structures of 377 approved drug targets retrieved from the DrugBank. Intriguingly, the majority of the top-ranked targets belong to protein kinases. Remarkably, consistent with the computational prediction, we found that pazopanib inhibits AchE with sub-micromolar affinity. We explored pazopanib for its ability to rescue memory dysfunction and cognitive decits in a rat model induced by quinolinic acid (QA). 18 For the rst time, we found that pazopanib is able to restore memory and cognitive decits to a similar extent as donepezil in a dosage of just 15 mg kg À1 .
Results
Two-dimensional drug screening of both affinity and specicity against AchE
The two-dimensional virtual screening of 1385 FDA-approved small molecule drugs (http://www.drugbank.ca/) against AchE was performed by the AutoDock 4.20 program (see Fig. 1 ). The binding affinity and ISR value for each molecule were recorded and used for the ranking. The 1385 approved drugs were used for making the contour map for the two-dimensional drug screening (Fig. 2b) Ligand virtual screening with 3D shape and electrostatic comparison
The three-dimensional shape comparison between donepezil and 1385 FDA-approved drugs (http://www.drugbank.ca/) was performed by the ROCS program implemented within OpenEye (Rapid Overlay of Chemical Structures, version 3.1, OpenEye Scientic Soware). The unique feature of ROCS is that it ranks compounds by their shape Tanimoto score, a quantitative assessment of three-dimensional overlap with a range from 0-1 (1 represents complete overlap). The molecule shape is computed by atom-centered overlapping Gaussian functions and the shape Tanimoto score is calculated by the maximal intersection of the volume of two molecules. The top 50 'hits' had Tanimoto scores between 0.65 and 0.83. Next, we re-ranked the ROCS hits for electrostatic similarity with donepezil by the program EON (version, 3.1, OpenEye, Scientic Soware), which computes the electrostatic Tanimoto score ranging from one (identical) to negative values judging by the overlap results of positive and negative charges. The electrostatic Tanimoto scores for the ROCS hits in the EON comparison ranged from À0.51 to 0.65. The nal top 50 hits were re-ranked by the score of EON_ET_Combo, which is the sum of the 3D similarity and electrostatic similarity. The results were then manually inspected. Nearly one third of the top 50 hits belong to antipsychotic and antidepressant drugs (17 out of 50, see ESI † Table 3 ). For practical reasons, they were ruled out from further experimental testing. Interestingly, sorafenib, pazopanib and sunitinib, three tyrosine kinase inhibitors (TKIs), are among the top 50 hits (see ESI † Table 3 ). Pazopanib and donepezil were superimposed and displayed using the VIDA program (version 3.1, OpenEye Scientic Soware) with a shape Tanimoto value of 0.612 and electrostatic Tanimoto score of 0.675 (Fig. 2d) .
Local binding site similarity of AchE with approved drug targets
The searching of local binding site similarity among multiple targets is essential for studying polypharmacology. 19 We compiled 377 FDA-approved drug targets from the DrugBank which led us to retrieve 1105 crystallographic structures from the PDB bank. Next, we searched and compared the pairwise ligand binding site similarity between AchE and the 1105 protein targets using TM-align, 20 a structure alignment and comparison tool recommended by the PDB bank (http:// www.pdb.org). Interestingly, 14 out of the top 20 targets ranked by local binding site similarity belong to the protein kinase family and the majority belong to the tyrosine kinase family including VEGFR2, EGFR, Src, JAK1, ERBB4, ERBB2, Lyn, JAK2, FGFR2, MAPK2 and HCK (see ESI † Tables 1 and 2 ). The remaining protein targets belong to the carboxylesterase, opioid receptor and phospholipase families, etc. The pairwise similarity TM-score between the pocket of VEGFR2 and AchE is about 0.31 (TM-score > 0.30 suggests signicance, see Fig. 2c , ESI † Tables 1 and 2 ).
AchE enzymatic assay screening
The AchE enzymatic assay screening experiments determined that pazopanib is the most potent molecule among thirteen TKIs with an IC 50 value of 0.93 mM (see Fig. 2e ). The IC 50 value of sunitinib is 5.87 mM. Sorafenib as well as other TKIs are weak binders for AchE (IC 50 > 10 mM, see ESI † Table 4 for details).
Pazopanib binds with AchE similarly to donepezil
We performed molecular docking combined with molecular dynamics (MD) simulations to assess the possible binding mode of pazopanib with AchE. In short, the MD simulations (three independent 300 ns simulation and one independent 1000 ns simulation) revealed that pazopanib can t well into the pocket of AchE (see Fig. 3 , see Fig. 3b ). These results suggest that pazopanib binds with AchE similarly to donepezil.
Effects of pazopanib on cognition impairment of a rat model in the novel object recognition test
To assess whether pazopanib can restore cognition decits, we used the novel object recognition test 22 as a behavioral assay to evaluate recognition memory. Compared to the control group, the model group showed signicant impairment in novel object exploration/recognition. On the other hand, both the group treated with donepezil and the group treated with pazopanib showed improved performance in the novel object recognition test (see Fig. 4a and b) . The group treated with pazopanib in a high dose (15 mg kg À1 ) returned this phenotype to a similar extent as the treatment group with donepezil (0.95 mg kg À1 ).
Effects of pazopanib on memory dysfunction in the Y maze cognitive behavioral assay
The Y maze cognitive behavioral assay 23 is conducted to measure the short-term working memory for model rats treated with pazopanib and donepezil. A signicantly lower spontaneous alternation response rate was observed for the model group compared to the control group injected with PBS solution. In contrast, the group treated with pazopanib restored this phenotype to a similar extent as the group treated with donepezil ( Fig. 4c and d) . These data indicate that pazopanib can improve the short-term working memory of animals in a similar manner to donepezil.
Effect of pazopanib on spatial memory impairment in the Morris water maze
The Morris water maze (MWM) task demands incremental learning of a xed platform location throughout the training period which results in the formation of spatial reference memory. 24 Compared to the control-group rats (control group), we observed that the model group spent signicantly more time and distance in nding the hidden platform. On the other hand, when donepezil (0.95 mg kg À1 ) was administered by intragastric infusion, the model rats showed a signicant decrease in time and distance spent to nd the hidden platform. Interestingly, when pazopanib was administered to the model rats, they showed a similar decrease in time and distance spent to nd the hidden platform in a dose dependent manner (see Fig. 5a and b) . Subsequently, we performed probe trial experiments in which the platform was removed. The model rats with spatial memory decits were unable to develop a spatial preference for the area around the platform. By contrast, the control group as well as the model group administered with donepezil or pazopanib demonstrated a clear spatial preference in the correct quadrant of the platform ( Fig. 5c and d) . Moreover, bivariate histograms of the swimming patterns revealed that the group treated with pazopanib (15 mg kg À1 ) also developed a spatial preference in the correct quadrant with the platform removed (Fig. 5d) . Together, the above results suggest that pazopanib can reverse the spatial memory decits in a fashion similar to donepezil.
Pazopanib enhances hippocampal Ach levels in the model rats
We used an ELISA assay to detect acetylcholine (ACh) levels in the hippocampus of the control and drug-treated rat groups. In agreement with prior ndings, 25 the QA-induced rats demonstrate a signicant reduction in hippocampal Ach release compared to the control group. Remarkably, pazopanib administration was able to prevent the QA-induced decrease in ACh level in a dose dependent manner (see Fig. 6a ). The benecial effect of 15 mg kg À1 of pazopanib was similar in extent to that seen in the donepezil-treated group. This demonstrates that pazopanib prevents cholinergic degeneration and enhances Ach levels in model rats.
Pazopanib increases the expression of synaptic markers in the model rats Synaptophysin (SYP) is a synaptic vesicle protein and has been widely used as a presynaptic marker for presynaptic terminals.
26
The expression level of SYP is signicantly correlated with cognitive degeneration and the progression of neurodegenerative diseases. 27, 28 We observed a decrease in the SYP level in the CA1 region of the model group compared to the control group by western blotting, whereas SYP expression level was increased in donepezil-and pazopanib-treated model rats (Fig. 6b and c) . In addition, PSD-95 is also a synaptic marker and plays an important role in synaptic maturation and pathogenesis of neurodegenerative disorders. 29 The effects of donepezil and pazopanib on the PSD-95 level in the hippocampus and the cerebral cortex of treated animals are not statistically signicant compared to the control group. Nevertheless, we observe a trend towards the decrease in the PSD-95 level in the model group and a trend towards the increase in the PSD-95 level in the donepezil-and pazopanib-treated groups (see ESI † Fig. 2 ). These data suggest that pazopanib might be able to protect the synapses and prevent the progression of neurodegenerative diseases.
Discussion
There are still unmet needs for disease-modifying therapies of neurodegenerative disorders with convenient dosing and excellent safety proles. The identication of approved drugs for new uses becomes an attractive strategy as a complement to conventional approaches. The established safety prole for existing drugs might substantially reduce the time and cost to advance candidate compounds into clinical trials. 30 Recently, minocycline, a tetracycline antibiotic used to treat bacterial infection has been found to reduce the level of pro-inamma-tory mediators and microglial activation in the AD mouse model. 31 However, notably, the benecial dosage of minocycline (40-50 mg per kg per day) in AD animals is about 1.25-1.45 fold Fig. 4 Effect of pazopanib on memory and cognition impairment in the novel object test and Y maze test. (a) The discrimination index for novel object recognition at 1 h into the test session; (b) the discrimination index for novel object recognition at 24 h into the test session. Results were expressed as the mean AE SEM (n ¼ 10-12) and analyzed with one-way ANOVA, followed by Dunnett's post test for multiple comparisons. ###P < 0.001 vs. the control group; ***P < 0.001, **P < 0.01, *P < 0.05 vs. the model group; (c and d) effect of pazopanib on the impairment of spontaneous alteration of behavior in the Y maze test in rats. Results were expressed as the mean AE SEM (n ¼ 10-12) and analyzed with one-way ANOVA, followed by Dunnett's post test for multiple comparisons. ###P < 0.001 vs. control group; ***P < 0.001, **P < 0.01, *P < 0.05 vs. model group.
higher than the recommended maximum clinical dose for the treatment of bacterial infection. More recently, Cramer et al. have found that the drug bexarotene, which is FDA-approved for the treatment of cutaneous T cell lymphoma, can rapidly reverse memory decits in the AD mouse model. 32 However, the effective dosage of bexarotene used in AD animal models was 3-fold higher than that used in clinical cancer treatment. Therefore, it is of priority to nd candidate compounds to treat AD and other neurodegenerative disease with acceptable dosages and tolerability for older patients.
In light of this, we designed a computational strategy of coupling two-dimensional virtual and ligand-based screening with analysis of 3D shape and electrostatic similarity, and comparison of local binding site similarity to search approved drugs for the treatment of AD and other neurological disorders (see Fig. 1 ). The intrinsic specicity ratio (ISR) for discrimination based on the energy landscape theory of ligand binding 7 has been demonstrated to be well-correlated with the structural t or structural specicity. Therefore, the concept of twodimensional screening has the advantages of considering both affinity and specicity, the two requirements for efficient biomolecular recognition. 33, 34 The comparison of ligand shape and electrostatic similarity is based on the rationale that two ligands similar in volume and physical-chemical properties are likely to have similar target-binding activities. For instance, this approach has been found quite useful by Churchill et al. 35 in the identication of the rst small molecular inhibitor of NAADP (nicotinic acid adenine dinucleotide phosphate). On the other hand, the local binding site similarity comparison is based on the hypothesis that similar binding sites most likely bind the same molecules. This approach has led to a few successful reports 36 such as the identication of HIV-protease inhibitor Nelnavir as an anti-cancer agent 37 and the identication of the PD drug Comtan for the treatment of tuberculosis. 38 The ligand 3D shape and electrostatic similarity comparison of donepezil with 1385 approved drugs has indicated that three TKIs (sunitinib, pazopanib and sorafenib, see ESI † Table 3 ) are among the top 50 hits. We compared the binding pocket of AchE with the 1105 ligand binding sites of approved drug targets by a pairwise structure alignment and a similarity comparison tool. The local binding site similarity comparison study has concluded that the majority of the top-ranked hits (70%, 14 out of top 20, see ESI † Tables 1 and 2 ) belong to protein kinases among which 8 hits are for protein tyrosine kinases (PTK). We chose and purchased TKIs for further experimental testing for two practical reasons: (1) TKIs are among the top hits in our integrated computational pipelines; (2) TKIs are structurally divergent molecules with easy accessibility. We identied pazopanib as the most potent Results were expressed as the mean AE SEM (n ¼ 10-12) and analyzed with repeated measures ANOVA followed by Dunnett's post test for multiple comparisons. ###P < 0.001 vs. the control group; ***P < 0.001, **P < 0.01, *P < 0.05 vs. the model group; (c) effect of pazopanib on spatial memory impairment in the probe test of the water maze test in rats. The vertical axis represents the time spent in the fourth quadrant where the platform was located. Results were expressed as the mean AE SEM (n ¼ 10-12). ##P < 0.01 vs. the control group; **P < 0.01, *P < 0.05 vs. the model group; (d) spatial preference in the probe test of the water maze test. The heat map is used to represent the frequently visited areas as orange and red. The frequency of crossing is calculated as (number of crossings at each point)/(maximum number of crossings at all points). Red represents the most frequently visited areas. The location of the platform is represented as a black circle.
molecule with sub-micromolar affinity among the 13 purchased TKIs by enzymatic assay (see ESI † Table 4 ). Notably, this is the rst report of integrating two-dimensional virtual screening, ligand-based screening and comparison of local binding site similarity to narrow down the list of candidate molecules for further experimental testing.
Our results suggest that pazopanib restored memory loss and cognition impairment in a rat model induced by quinolinic acid (QA). We found that pazopanib improves learning and memory decits in a dose-dependent manner through in vivo experiments. In particular, pazopanib treatment at a dosage of 15 mg kg À1 prevented the QA-induced neurodegeneration to a similar extent as donepezil at a dosage of 0.95 mg kg À1 for rats, equivalent to the maximum dosage of 10 mg per day for human. This is signicant because our ndings demonstrated that pazopanib restored the cognition and memory decits at only one h of the equivalent dosage used for the treatment of carcinoma (the recommended clinical dosage of pazopanib is 800 mg daily for cancer treatment 39 ). Hence, the risk of side effects for pazopanib in the treatment of neurodegenerative diseases might be minimal, given its well-tolerated safety prole in cancer treatment.
In the present study, we demonstrated the efficacy of pazopanib using the QA-induced animal model because it has been well established that QA leads acutely to the loss of cholinergic neurons and therefore reproduces the neuroinammatory events in diseases including AD, PD and HD. 40, 41 Moreover, the QA-induced animal model has been widely used as it resembles common pathological features of neurodegenerative disorders. 42, 43 However, given that the exact pathways or pathologies of neurodegenerative diseases are not denitely identied and continue to be a source of debate, one single animal model is insufficient to determine the effects of pazopanib for neurodegenerative disorders. Therefore, further studies in various animal models 44 are warranted to assess pazopanib as an effective therapeutic for neurodegeneration.
In summary, by integrating methods of two-dimensional screening, ligand-based virtual screening, computational modeling and in vitro and in vivo experimental testing, we predicted and found that pazopanib is a sub-micromolar affinity ligand of AchE and is capable of ameliorating memory and cognitive dysfunctions that characterize neurodegenerative disorders. Notably, pazopanib showed a similar extent of activities as donepezil at a much lower dosage than that used to treat cancer. Another signicance of the present work is that we provide a useful paradigm for evaluating new uses for approved drugs. In particular, the concept of virtual screening based on both affinity and specicity could be generally applied in the drug discovery pipeline. Neurodegeneration is a form of multifactorial disease and a variety of mechanisms may contribute to its pathogenesis. Further studies are warranted to clarify the detailed mechanism and the impact of pazopanib for The increase in Ach level in the hippocampus after treatment with donepezil or pazopanib in the rat model. Results were expressed as the mean AE SEM (n ¼ 6) and analyzed with one-way ANOVA, followed by Dunnett's post test for multiple comparisons. ###P < 0.001 vs. the control group; ***P < 0.001, *P < 0.05 vs. the model group; (b and c) effect of pazopanib on the expression of synapse-related protein SYP in the hippocampus and the cerebral cortex of the rat model. The intensity of each protein band was quantified by densitometry using the Quantity One software (Bio-Rad, Hercules, CA, USA), and then corrected using the corresponding b-actin level. Results were expressed as the mean AE SEM (n ¼ 6) and analyzed with one-way ANOVA, followed by Dunnett's post test for multiple comparisons. ###P < 0.001 vs. the control group; ***P < 0.001 vs. the model group.
the treatment of neurodegeneration. To the best of our knowledge, this is the rst report on the effect of pazopanib in abrogating memory and cognitive decits under in vivo conditions.
Materials and methods

Two dimensional screening of approved drugs
The Autodock 4.20 program was used to perform the twodimensional screening of approved small molecule drugs against AchE. For each molecule, we calculated the binding affinity, the energy gap between the lowest binding energy state and average binding energy and the variance in the free energies of different binding modes. The congurational entropy, which measures the size of the congurational space that scales with the size of the system (number of atoms), is also calculated. The ISR value is calculated as dE DE ffiffiffiffiffi 2S p .
Ligand virtual screening by shape and electrostatics
We used OMEGA 2.4.6 to generate 100 conformers for each molecule of 1385 approved drugs. The input donepezil structure was entered as a query molecule for the initial screening. We used ROCS (3.1.2) for 3-dimensional shape comparisons and the top 500 hits were output in the order of shape Tanimoto values. For comparisons of electrostatic properties (EON 2.10), the lowest-energy conformer of donepezil was used for all comparisons to re-rank the top 500 ROCS hits in the order of electrostatic Tanimoto scores. Lastly, the top 50 hits were ranked by EON_combo, the sum of 3D shape Tanimoto score and electrostatic Tanimoto score (ESI † Table 3 ).
Local binding site similarity search
The crystallographic structure of AchE complexed with donepezil has been solved (PDB ID: 1EVE). 1105 protein target structures co-crystallized with ligands from the PDB bank (http://www.pdb.org/) were compiled for use. Herein, the ligand binding pocket was dened as the residues within 8Å of the complexed ligand and the ligand binding pockets of the 1200 protein targets were extracted using the Pymol program (Educational version 1.3). Amino acid residues within 8Å of the co-crystallized ligand were dened as the ligand binding pocket. The TM-align program was then used to compute the pairwise ligand binding site similarity between human AchE and 1105 protein targets. The alignment results were ranked in descending order (see ESI † Tables 1 and 2 ).
Animals used in the experiments
The experiments were performed strictly following the ethics regulation and institutional guidelines of Shenyang Pharmaceutical University. The Sprague-Dawley (SD) rats were maintained at 21 C in standard ventilated cages holding 3 rats per cage and water ad libitum.
Rodent model of neurodegeneration induced by quinolinic acid (QA)
An injection of 2 ml PBS solution (pH 7.4) containing 120 nmol quinolinic acid (QA; Sigma, Shanghai) was applied to both le and right nucleus basalis of Meynert (NBM) of the animals following the standard protocol. The control group animals received an injection of 2 ml of the vehicle PBS solution.
Drug treatment of the experimental animals
For treating experimental rats, donepezil and pazopanib (as salts) were dissolved in physiological saline containing 0.5% Tween-80. Experimental rats received a daily dose of drugs or vehicle by intragastric administration until the end of the experiments. For the behavioral assay, drug treatments were conducted aer the last trial of every day during the testing period.
Novel object recognition task
The object recognition task was performed in an open circle arena (80 cm Â 80 cm). Aer habituation, two identical objects (A1, A2) were placed in the arena with an equal distance to the edge. Subsequently, the rats were exposed to the familiar open arena and allowed to explore for 5 min. The time that rats spent exploring each object (t A1 , t A2 ) was recorded. Aer one hour, one object was replaced with a new object (B) and the time spent exploring each object (t A1 , t B ) was recorded. Similarly, aer 24 hours, object B was replaced with another new object C and the time spent exploring each object (t A1 , t C ) was recorded. The object preferential index and object discrimination index were used to evaluate the performance in object recognition and calculated as: (1) preferential index (1 h) ¼ t B /(t A1 + t B ); (2) preferential index (24 h) ¼ t C /(t A1 + t C ); (3) discrimination index (1 h) ¼ (t B À t A1 )/(t A1 + t B ); (4) discrimination index (24 h) ¼ (t C À t A1 )/(t C + t B ).
Y maze cognitive behavioral assay
During the experiments, each rat was rst placed at one end of the arm and the total number (N) and the order of the arm entries were recorded by video camera for every 8 minutes. Successful spontaneous alternations are dened as consecutive triple entries of different arms choices. The spontaneous alternation response rate is calculated as: spontaneous alternation rate (%) ¼ number of successful alternation/(N À 2) Â 100.
Morris water maze task and probe trial test
In brief, the water maze consisted of a dark gray pool lled with opaque water. The testing platform was hidden below the opaque water surface but accessible for the rats. The animals were subjected to two trials per day for 4 days with a video system monitoring and recording the percentage of time spent in the various quadrants. On the next day, the platform was removed and each rat was allowed to explore in the water pool for 90 s. The swimming time and the swimming distance in the quadrant where the platform was located were calculated.
